DDInter388 DDInter1676
Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] Citalopram enhances serotonergic transmission through the inhibition of serotonin reuptake, and among all the SSRIs, citalopram appears to be the most selective toward serotonin reuptake inhibition.[A261316,A14720] Specifically, it has a very minimal effect on dopamine and norepinephrine transportation and virtually no affinity for muscarinic, histaminergic, or GABAergic receptors. Citalopram was approved by the FDA in 1998 for the treatment of depression in adults 18 years or older.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Citalopram {u} (Compound) resembles {v} (Compound) Escitalopram
Citalopram {u} (Compound) treats {v} (Disease) alcohol dependence
Citalopram {u} (Compound) binds {v} (Gene) HTR2C
Citalopram {u} (Compound) upregulates {v} (Gene) PLS1
Citalopram {u} (Compound) palliates {v} (Disease) panic disorder
Citalopram {u} (Compound) downregulates {v} (Gene) RNH1
Citalopram {u} (Compound) causes {v} (Side Effect) Allergy aggravated
Citalopram {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cobicistat
Citalopram {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Citalopram {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enoxaparin
Citalopram (Compound) resembles Escitalopram (Compound)
Citalopram (Compound) treats alcohol dependence (Disease)
Citalopram (Compound) binds HTR2C (Gene)
Citalopram (Compound) upregulates PLS1 (Gene)
Citalopram (Compound) palliates panic disorder (Disease)
Citalopram (Compound) downregulates RNH1 (Gene)
Citalopram (Compound) causes Allergy aggravated (Side Effect)
Citalopram may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Citalopram may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Enoxaparin